Indiana Medicaid and GLP-1 coverage

The exclusion is a rule, not a formulary decision, and it is written broadly. Indiana's Pharmacy Services provider reference module reproduces 405 IAC 5-24-3(b): "The following are not covered by Medicaid: (1) Anorectics or any agent used to promote weight loss. (2) Topical minoxidil preparations. (3) Fertility enhancement drugs. (4) Drugs when prescribed solely or primarily for cosmetic purposes." The phrase that does the work is "any agent used to promote weight loss", which follows the purpose rather than the drug class.

Indiana Health Coverage Programs, Pharmacy Services provider reference module (PROMOD00042, version 8.0), reproducing 405 IAC 5-24-3, effective August 2025 · source

The criteria put the exclusion in the heading above each drug, so a prescriber cannot miss it. The document's section headings read "ZEPBOUND (TIRZEPATIDE) (NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS)", "WEGOVY (SEMAGLUTIDE) INJECTION FORMULATION (NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS)" and "WEGOVY (SEMAGLUTIDE) ORAL FORMULATION (NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS)". Every page of the document is footed 07.01.2026.

Indiana Medicaid, "Criteria for Indiana Medicaid GLP-1 Receptor Agonists and Combinations", prepared for the State of Indiana by OptumRx, effective July 2026 · source

Zepbound has one door and it is sleep apnea, with a diagnosis you must not have. Initial authorization runs a year and requires that the "Member is 18 years of age or older", a "Diagnosis of moderate to severe obstructive sleep apnea (OSA) (i.e., apnea hypopnea index (AHI) of ≥ 15 events/hour) in individuals with obesity", and a "documented BMI of ≥ 30 kg/m2 before initiating Zepbound". The sleep study must be "reviewed and interpreted by a sleep medicine-certified physician". Renewing asks for a reduction in AHI and that the "Member demonstrates a meaningful weight loss from baseline (defined as a weight loss of at least 5% from baseline)", while the prescriber attests the "Member does not have Type 1 or Type 2 diabetes mellitus".

Indiana Medicaid, "Criteria for Indiana Medicaid GLP-1 Receptor Agonists and Combinations", effective July 2026 · source

Wegovy's door is cardiovascular, and it has an age floor higher than the drug's label. The criteria require a "Diagnosis of cardiovascular disease (CVD) in obese or overweight individuals who need risk reduction of major adverse cardiovascular events (MACE)" together with all of: "Member is 45 years of age or older", a "BMI of ≥ 27 kg/m2", and a documented prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease. Liver disease is the other route, through MASH or MASLD.

Indiana Medicaid, "Criteria for Indiana Medicaid GLP-1 Receptor Agonists and Combinations", effective July 2026 · source

Under 21 the answer is different, and the state said so in a dated bulletin. "The Indiana Health Coverage Programs (IHCP) may cover weight-loss medications for eligible Medicaid members under the age of 21 through the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) program." It names "Wegovy (semaglutide) and Saxenda (liraglutide)", says decisions "will be on a case-by-case basis using peer-reviewed literature", asks that requests "include a diagnosis of morbid obesity with comorbid conditions and documentation of nutritional counseling and/or weight-loss programs", and adds that "Reassessments of medical necessity for continued authorization will occur every six months."

Indiana Health Coverage Programs, Bulletin BT2023148, "IHCP to cover weight-loss medications in select cases under EPSDT", effective October 2023 · source

The current criteria were set by a dated action of the state's drug utilization review board rather than by a quiet list update, which is what lets a reader date them. Bulletin BT202664, published April 30, 2026, records the board's April 17, 2026 meeting and the GLP-1 receptor agonist and GIP receptor agonist prior authorization criteria that follow from it.

Indiana Health Coverage Programs, Bulletin BT202664, effective April 2026 · source

One list binds fee-for-service and managed care alike, which is unusual and is stated on the document itself. Every page of the Statewide Uniform Preferred Drug List is footed "Effective for FFS and Managed Care Organization claims submitted on or after August 1, 2026." It carries no anti-obesity or weight-management class at all: across its 129,191 characters the strings "anti-obesity" and "obes" appear zero times and Saxenda and Foundayo appear zero times, against a control of 18 occurrences of "insulin". The GLP-1s that do appear are grouped in a class whose entry reads "PA criteria must be met for the following".

Indiana Medicaid, Statewide Uniform Preferred Drug List (SUPDL), effective August 2026 · source

Indiana's filing window is 33 calendar days, which is not a number any other state on this site uses, and the clock runs from the later of two events. Its member module states: "All FFS member appeals for healthcare actions must be filed within 33 calendar days of the date the adverse decision was received or takes effect, whichever is later." Managed care runs differently — a member who has been through their entity's appeal can seek review by "an independent review organization (IRO) within 120 days from the date of the MCE's decision."

Indiana Health Coverage Programs, Member Eligibility and Benefit Coverage provider reference module (PROMOD00009, version 8.5), effective September 2026 · source